Eupraxia Pharmaceuticals Inc.
EPRX
$8.08
-$0.17-2.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -50.21M | -44.47M | -38.58M | -29.37M | -28.96M |
| Total Depreciation and Amortization | 360.80K | 281.30K | 237.70K | 219.40K | 194.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.73M | 8.69M | 10.50M | 4.27M | 4.63M |
| Change in Net Operating Assets | 5.65M | 2.80M | -713.70K | 86.60K | -6.35M |
| Cash from Operations | -37.47M | -32.70M | -28.55M | -24.80M | -30.48M |
| Capital Expenditure | -753.80K | -746.90K | -588.90K | -439.90K | -421.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 600.00 | 600.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.72M | -79.72M | -- | -- | -- |
| Cash from Investing | -80.48M | -80.47M | -588.90K | -439.40K | -421.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -4.60M |
| Issuance of Common Stock | 143.97M | 144.21M | 76.06M | 106.30M | 32.40M |
| Repurchase of Common Stock | -1.79M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.27M | -- | -- | -- | -- |
| Cash from Financing | 151.45M | 144.21M | 76.06M | 106.30M | 27.80M |
| Foreign Exchange rate Adjustments | -835.60K | 1.10K | 544.80K | -764.60K | -448.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.66M | 31.05M | 47.46M | 80.30M | -3.55M |